Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11895588 | 1.00 | TRPA1 (0.40) | TRPA1ALDH1A1GAAMAPTMAPK1 | |
| SCHEMBL11954733 | 1.00 | TRPA1 (0.40) | TRPA1ALDH1A1GAAMAPTMAPK1 | |
| SCHEMBL11954708 | 1.00 | TRPA1 (0.40) | TRPA1ALDH1A1GAAMAPTMAPK1 | |
| SCHEMBL11895602 | 0.88 | TRPA1 (0.51) | TRPA1SMN1; SMN2KCNH3HTTNPC1 | |
| SCHEMBL11895244 | 0.88 | TRPA1 (0.51) | TRPA1SMN1; SMN2KCNH3HTTNPC1 | |
| SCHEMBL11895480 | 0.88 | TRPA1 (0.51) | TRPA1SMN1; SMN2KCNH3HTTNPC1 | |
| SCHEMBL2905 | 0.86 | TRPA1 (0.37) | TRPA1ALDH1A1GAAMAPTMAPK1 | |
| SCHEMBL14682 | 0.86 | TRPA1 (0.37) | TRPA1ALDH1A1GAAMAPTMAPK1 | |
| SCHEMBL11954736 | 0.86 | TRPA1 (0.37) | TRPA1ALDH1A1GAAMAPTMAPK1 | |
| SCHEMBL11895757 | 0.83 | TRPA1 (0.38) | TRPA1ALDH1A1MAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196894-A1 | NOVEL TRPA1 ANTAGONISTS | SCHERING CORPORATION | 2012-08-02 | — | — | US | disclosed |
| WO-2011043954-A1 | NOVEL TRPA1 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196894-A1 | NOVEL TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885ALDH1A1 3703/4885GAA 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.